Tillmann Schnierda

Director, Commercial Development, Mammalian at Lonza

Speaker

Tillmann joined the Vacaville site in October 2024, where he manages the commercial strategy and product portfolio of the site. In addition, with Vacaville being the newest addition to the Lonza network, he also supports its integration.

The addition of Vacaville in October 2024 significantly enhances Lonza’s large scale mammalian network. By adding 332kL of fully operational and FDA approved manufacturing capacity, the site is poised to meet customers’ immediate late clinical and commercial manufacturing needs.

Prior to his current position, Tillmann held various operational positions

within Lonza’s mRNA and Microbial business units at the Visp (Switzerland) and Geleen (Netherlands) sites. He has extensive experience in technical transfers, having started his Lonza career in Microbial where he spent five years in manufacturing and MSAT functions, managing small to large scale tech transfers and commercial campaigns. During the pandemic, he was instrumental in the transfer, ramp up and commercial manufacturing of mRNA vaccines. More recently, he led the ramp up of an mRNA LNP process development and clinical GMP facility in Geleen (Netherlands) as Head of Operations for two years.

Tillmann holds a Master of Science in Pharmaceutical Bioprocess Engineering from the Technical University Munich. For his Master Thesis, he spent one year at the Stellenbosch University in South Africa.